Roivant Acquires GSK’s CNS Drug

Roivant Neurosciences Ltd. has entered into an agreement with GlaxoSmithKline to acquire SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders.
 
GSK conducted 13 clinical studies of SB742457 in more than 1,250 healthy subjects and Alzheimer’s disease patients. The results provide evidence that SB742457 holds promise for patients with mild-to-moderate Alzheimer’s disease. Roivant will continue development of SB742457 for the treatment of the signs and symptoms of mild-to-moderate Alzheimer’s disease, as well as other neurological disorders.
 
“This transaction represents a foundational late-stage clinical asset for Roivant,” said Vivek Ramaswamy, founder and director of Roivant Sciences Ltd. and chief executive officer. “Our organization is fully committed to building on the research already completed by GSK and advancing a new therapeutic option for Alzheimer’s disease, a debilitating and deadly disease that affects millions of patients and their families.”